Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļONCY
āļāļ·āđāļāļāļĢāļīāļĐāļąāļOncolytics Biotech Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 05, 2001
āļāļĩāļāļĩāđāļKelly (Jared Ryan)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ- -
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļOct 05
āļāļĩāđāļāļĒāļđāđ804, 322 - 11 Avenue Sw
āđāļĄāļ·āļāļCALGARY
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻCanada
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđT2R 0C5
āđāļāļĢāļĻāļąāļāļāđ14036707377
āđāļ§āđāļāđāļāļāđhttps://www.oncolyticsbiotech.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļONCY
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 05, 2001
āļāļĩāļāļĩāđāļKelly (Jared Ryan)
Mr. Kirk J. Look
Chief Financial Officer
Ms. Allison Hagerman
Vice President - Product Development
Vice President - Product Development
Ms. Amy G. Levin
Vice President - Clinical Operations
Vice President - Clinical Operations
Ms. Deborah M. Brown
Independent Director
Mr. Jared Kelly
Chief Executive Officer, Director
Chief Executive Officer, Director
Mr. Andrew Aromando
Chief Business Officer
Mr. James T. (Jim) Parsons, CPA
Mr. James T. (Jim) Parsons, CPA
Independent Director
Dr. Thomas C. Heineman, Ph.D.
Dr. Thomas C. Heineman, Ph.D.
Chief Medical Officer of Oncolytics Biotech (U.S.)
Chief Medical Officer of Oncolytics Biotech (U.S.)
Ms. Angela Frances Holtham
Ms. Angela Frances Holtham
Independent Director
Mr. Jon Patton
Director - Investor Relations and Communication
Director - Investor Relations and Communication
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Kirk J. Look
Chief Financial Officer
Ms. Allison Hagerman
Vice President - Product Development
Vice President - Product Development
Ms. Amy G. Levin
Vice President - Clinical Operations
Vice President - Clinical Operations
Ms. Deborah M. Brown
Independent Director
Mr. Jared Kelly
Chief Executive Officer, Director
Chief Executive Officer, Director
Mr. Andrew Aromando
Chief Business Officer
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ